Research Article
BibTex RIS Cite

Polikistik over sendromunda disfonksiyonel HDL'nin göstergesi olarak miyeloperoksidaz/paraoksonaz1 oranının değerlendirilmesi

Year 2023, Volume: 20 Issue: 3, 1804 - 1809, 01.10.2023
https://doi.org/10.38136/jgon.1313215

Abstract

Amaç: Miyeloperoksidaz/paraoksonaz1(MPO/PON1) oranının, oksidatif stresin bir ölçüsü olan disfonksiyonel HDL(d-HDL)'yi yansıttığı bilinmektedir. Bu çalışmada, polikistik over sendromunda (PKOS) MPO/PON1 oranının değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntem: Bu prospektif çalışmaya toplam 123 kadın dahil edildi. PKOS tanılı kadınları içeren çalışma grubu (n=63), sağlıklı kadınların bulunduğu kontrol grubu (n=60) ile karşılaştırıldı. Grupların sosyodemografik özellikleri ve klinik özellikleri kaydedildi. Serum HDL düzeyi, MPO ve PON1 aktiviteleri değerlendirildi.
Bulgular: PKOS hastalarında MPO aktivitesinde artış ve PON1 aktivitesinde azalma gözlendi (sırasıyla; p<0,0001 ve p=0,007). Sağlıklı kontrollere kıyasla PKOS hastalarında d-HDL anlamlı olarak yüksek bulundu (0,50 (0,12) vs. 0,56 (0,24), p<0,0001). Oksidatif parametreler ile PKOS ilişkili bulgular arasında da anlamlı ilişkiler gözlendi (p<0.05).
Sonuç: Çalışmamızda, d-HDL olarak tanımlanan artmış MPO/PON1 oranının yanı sıra artmış MPO ve azalmış PON1 aktiviteleri de PKOS hastalarında artmış oksidatif stresi desteklemektedir. Sonuçlarımız, yaşamının erken dönemlerinde bile PKOS hastalarında oksidatif stres ve dislipidemiye işaret etmesi yönünden dikkat çeker niteliktedir.

References

  • 1. Escobar-Morreale HF. Polycystic ovary syndrome: de- finition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84. 2. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analy- sis. Hum Reprod Update. 2011;17(4):495-500. 3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-1007. 4. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjato- vic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604-12. 5. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fo- narow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8.

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Year 2023, Volume: 20 Issue: 3, 1804 - 1809, 01.10.2023
https://doi.org/10.38136/jgon.1313215

Abstract

Aim: The myeloperoxidase/paraoxonase1(MPO/PON1) ratio is known to reflect the dysfunctional HDL(d-HDL) which is a measure of oxidative stress. This study aimed to evaluate the MPO/PON1 ratio in polycystic ovary syndrome(PCOS).
Materials and Method: This prospective study included a total of 123 patients. The study group including the women with the diagnosis of PCOS (n=63) was compared to the control group including the healthy women (n=60). Sociodemographic characteristics, and clinical features of the groups were recorded. Serum HDL level, MPO, and PON1 activities were evaluated.
Results: The PCOS patients were observed to have increased MPO and decreased PON1 activities (p<0.0001 and p=0.007, respectively). The d-HDL and was found to be significantly higher in PCOS patients compared to the healthy controls (0.56 (0.24) vs. 0.50 (0.12), p<0.0001). There were also significant associations between the oxidative parameters and PCOS related findings (p<0.05).
Conclusion: Besides the increased MPO/PON1 ratio which defined as d-HDL, the increased MPO and decreased PON1 activities also supported the increased oxidative status in PCOS patients. Our results may be considered to draw attention to oxidative stress and dyslipidemia in PCOS patients, even in the early periods of the women life.

References

  • 1. Escobar-Morreale HF. Polycystic ovary syndrome: de- finition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84. 2. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analy- sis. Hum Reprod Update. 2011;17(4):495-500. 3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-1007. 4. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjato- vic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604-12. 5. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fo- narow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8.
There are 1 citations in total.

Details

Primary Language English
Subjects Obstetrics and Gynaecology
Journal Section Research Articles
Authors

Esin Merve Erol Koç 0000-0001-7686-9149

Selen Yaman 0000-0001-5247-6615

Meryem Ceyhan 0000-0003-1341-1370

Salim Neselioglu 0000-0002-0974-5717

Özcan Erel 0000-0002-2996-3236

Melike Doğanay 0000-0002-2603-1812

Publication Date October 1, 2023
Submission Date June 12, 2023
Acceptance Date July 6, 2023
Published in Issue Year 2023 Volume: 20 Issue: 3

Cite

Vancouver Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. JGON. 2023;20(3):1804-9.